Atai Beckley Inc(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ATAI Atai Beckley Inc

盘后交易 05-14 18:24:10 EDT

4.04

-0.20

-4.72%

盘后4.06

+0.02+0.50%

18:16 EDT

最高4.24	最低4.03	成交量287.83万
今开4.24	昨收4.24	日振幅4.95%
总市值14.83亿	流通市值12.48亿	总股本3.67亿
成交额1,174万	换手率0.93%	流通股本3.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ATAI","market":"US","secType":"STK","nameCN":"Atai Beckley Inc","latestPrice":4.04,"timestamp":1778788800000,"preClose":4.24,"halted":0,"volume":2878273,"hourTrading":{"tag":"盘后","latestPrice":4.06,"preClose":4.04,"latestTime":"18:16 EDT","volume":26993,"amount":109353.98761400001,"timestamp":1778796975006,"change":0.02,"changeRate":0.00495,"amplitude":0.022277},"delay":0,"changeRate":-0.047169811320754755,"floatShares":309000000,"shares":367000000,"eps":-2.913693,"marketStatus":"盘后交易","change":-0.2,"latestTime":"05-14 18:24:10 EDT","open":4.24,"high":4.24,"low":4.03,"amount":11744430.314102,"amplitude":0.049528,"askPrice":4.13,"askSize":1000,"bidPrice":4.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.913693,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778803200000},"marketStatusCode":4,"adr":1,"adrRate":2,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":4.24,"preHourTrading":{"tag":"盘前","latestPrice":4.25,"preClose":4.24,"latestTime":"09:29 EDT","volume":32596,"amount":138947.425544,"timestamp":1778765375134,"change":0.01,"changeRate":0.002358,"amplitude":0.025943},"postHourTrading":{"tag":"盘后","latestPrice":4.06,"preClose":4.04,"latestTime":"18:16 EDT","volume":26993,"amount":109353.98761400001,"timestamp":1778796975006,"change":0.02,"changeRate":0.00495,"amplitude":0.022277},"volumeRatio":0.685756,"impliedVol":0.8888,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/ATAI","defaultTab":"news","newsList":[{"id":"1122175475","title":"Atai Beckley公布Emp-01（口服R-MDMA）二期a阶段追加结果：社交焦虑障碍改善显著且持续","url":"https://stock-news.laohu8.com/highlight/detail?id=1122175475","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122175475?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:20","pubTimestamp":1776853221,"startTime":"0","endTime":"0","summary":"Atai Beckley公司近日发布了其候选药物Emp-01（口服R-MDMA）在二期a阶段临床试验中的进一步数据。结果显示，该药物在治疗社交焦虑障碍方面表现出显著且一致的改善效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114413766","title":"Atai Beckley Inc：Emp-01总体安全且耐受性良好，未出现严重或重度不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1114413766","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114413766?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:20","pubTimestamp":1776853211,"startTime":"0","endTime":"0","summary":"Atai Beckley Inc宣布，其研究性药物Emp-01在临床试验中展现出良好的安全性与耐受性特征。试验数据显示，未报告任何严重的或重度的不良事件，表明该药物的安全性符合预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165930597","title":"Atai Beckley Inc：Emp-01在第43天展现出患者报告的悲伤症状大幅且具临床意义的降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1165930597","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165930597?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:18","pubTimestamp":1776853107,"startTime":"0","endTime":"0","summary":"Atai Beckley Inc宣布，其候选药物Emp-01在第43天的试验数据中，显示出对患者自我报告的悲伤症状产生了大幅度的降低，且这一改善具有临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ATAI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742200","title":"特朗普签署行政令加速PTSD疗法研发：美迷幻药物板块迎来“结构性拐点”，盘前全线飙升！","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742200","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628742200?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:23","pubTimestamp":1776684215,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在美国总统特朗普签署了一项旨在加速研究并扩大对用于治疗创伤后应激障碍的海外物质的获取渠道的行政令后，迷幻药物相关股票在盘前交易中上涨。投行奥本海默分析师杰伊·奥尔森表示，特朗普的行政令“通过促进研究、简化监管时间表和扩大患者获取渠道，代表了美国迷幻药物行业的一个结构性拐点，这强化了我们的积极展望”。报告指出，这是该领域取得的又一积极进展，利好 RBC 覆盖的迷幻药物公司：Definium Therapeutics、Compass Pathways 和 GH Research。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"88f7b346cf902c973ba59a5779bb445e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430797.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ATAI","BK4127","GHRS","LU2065731478.USD","LU0708994859.HKD","LU1267930573.SGD","HELP","BK4207","LU0029864427.USD","IE00BLDYK493.USD","BK4559","BK4009","BK4539","IE00B64QTZ34.USD","BK4161","LU0310800379.SGD","CMPS","BK4139","LU0128525929.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1193716026","title":"BPL-003展现快速持久抗抑郁疗效，难治性抑郁症迎突破；IIa期数据发表于《精神药理学杂志》，III期项目按计划2026年第二季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1193716026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193716026?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:01","pubTimestamp":1773741689,"startTime":"0","endTime":"0","summary":"针对难治性抑郁症的新型疗法BPL-003在临床研究中展现出快速且持久的抗抑郁效果，为治疗困境带来曙光。其IIa期临床试验数据已正式发表于权威期刊《精神药理学杂志》，验证了该疗法的潜力。最新公布的研究结果显示，BPL-003在用药后数小时内即产生显著抗抑郁作用，且疗效可持续数周。业界专家指出，BPL-003的快速起效特性在难治性抑郁症治疗领域具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190188906","title":"异动解读 | 抑郁症药物BPL-003将进入后期试验，Atai Beckley Inc盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190188906","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190188906?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:45","pubTimestamp":1773153956,"startTime":"0","endTime":"0","summary":"生物制药公司Atai Beckley Inc今日盘中股价大幅上涨5.01%，引起了市场关注。消息面上，公司宣布其针对耐药性抑郁症的实验性药物BPL-003在获得美国食品药品监督管理局的积极反馈后，计划于2026年第二季度进入三期临床试验阶段。此外，Atai Beckley在近日的投资者日活动上重点介绍了其研发管线的多项关键里程碑，并重申公司现金流预计可持续至2029年初。这些积极的研发进展和稳健的财务前景，增强了投资者对公司未来增长潜力的信心，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157753060","title":"BPL-003三期临床试验计划将于2026年第二季度启动，此前已成功完成FDA二期结束会议；Atai Beckley在2026年投资者日上重点介绍关键研发里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1157753060","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157753060?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:03","pubTimestamp":1773136980,"startTime":"0","endTime":"0","summary":"在成功完成美国食品药品监督管理局（FDA）二期临床试验结束会议后，BPL-003的三期临床试验计划正按部就班地推进，预计将于2026年第二季度正式启动。这一重要进展标志着该药物研发项目迈入了关键阶段。\n与此同时，Atai Beckley Inc（简称Atai Beckley）在近日举办的2026年投资者日活动上，重点介绍了公司研发管线中的多项关键里程碑。公司管理层详细阐述了未来几年的战略布局和预期进展，展现了其对推动创新疗法发展的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156938216","title":"Atai Beckley Inc：提交文件拟由售股股东转售最多7430万股普通股——SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1156938216","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156938216?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:11","pubTimestamp":1773051076,"startTime":"0","endTime":"0","summary":"Atai Beckley Inc（简称：ATAI）已向美国证券交易委员会（SEC）提交文件，申请由售股股东转售最多7430万股普通股。此次转售计划涉及现有股东出售其持有的公司股份，而非公司发行新股。根据SEC的备案信息，该转售申请旨在为售股股东提供灵活性，以便在未来合适的市场条件下进行股份减持。此举通常意味着现有股东可能有意调整其投资组合或释放部分流动性，但具体出售时间、价格及数量将视市场情况而定。投资者需关注后续公告，以了解实际股份出售的进展及其对股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179136417","title":"Atai生命科学第四季度运营开支达5.71亿美元，每股亏损1.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179136417","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179136417?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:38","pubTimestamp":1772800687,"startTime":"0","endTime":"0","summary":"Atai生命科学最新财报显示，公司第四季度运营支出高达5.71048亿美元，凸显其研发投入规模。同期每股收益为-1.73美元，反映公司仍处于战略投入阶段。\n当季运营收入呈现-5.69982亿美元的负值，税前利润亦录得-5.4492亿美元的亏损。尽管营收规模仅110万美元，但该公司持续专注于精神健康领域的创新疗法开发。\n财报数据表明，Atai生命科学正通过大规模资金投入推进临床阶段项目，这种发展模式在生物科技领域颇具代表性。投资者将密切关注其管线项目的临床进展与资金使用效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184375835","title":"Atai Beckley Inc 宣布 BPL-003 针对难治性抑郁症的二期临床试验结束会议圆满成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1184375835","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184375835?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:06","pubTimestamp":1772539569,"startTime":"0","endTime":"0","summary":"Atai Beckley Inc 已顺利完成其候选药物 BPL-003 针对难治性抑郁症的二期临床试验结束会议。此次会议的圆满结束标志着该药物研发进程中的一个重要里程碑，为后续的临床开发计划奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613291982","title":"Ataibeckley Inc.盘中异动 临近午盘急速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613291982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613291982?lang=zh_cn&edition=full","pubTime":"2026-02-21 00:53","pubTimestamp":1771606391,"startTime":"0","endTime":"0","summary":"北京时间2026年02月21日00时53分，Ataibeckley Inc.股票出现波动，股价大幅上涨5.10%。截至发稿，该股报4.02美元/股，成交量131.443万股，换手率0.36%，振幅4.71%。Ataibeckley Inc.股票所在的生物技术行业中，整体涨幅为0.30%。Ataibeckley Inc.公司简介：AtaiBeckley Inc是一家处于临床试验阶段的生物制药企业，其使命是通过研发有效、见效迅速且便捷的心理健康治疗方案来改善患者状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221005311a70de43e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221005311a70de43e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4022","R","ATAI","BK4007","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612483281","title":"Ataibeckley Inc.盘中异动 早盘股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612483281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612483281?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:35","pubTimestamp":1771511712,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日22时35分，Ataibeckley Inc.股票出现波动，股价大幅下挫5.32%。截至发稿，该股报3.74美元/股，成交量21.3018万股，换手率0.06%，振幅4.55%。Ataibeckley Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Ataibeckley Inc.公司简介：AtaiBeckley Inc是一家处于临床试验阶段的生物制药企业，其使命是通过研发有效、见效迅速且便捷的心理健康治疗方案来改善患者状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223512a70a7f86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223512a70a7f86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4232","BK4007","ATAI","BK4539","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117155613","title":"Atai Beckley任命Michael Faerm为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1117155613","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117155613?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:06","pubTimestamp":1771502794,"startTime":"0","endTime":"0","summary":"2026年2月19日，临床阶段生物技术公司Atai Beckley Inc宣布，任命Michael Faerm为首席财务官，自2026年3月9日起生效。作为Atai Beckley的首席财务官，他将全面负责公司的财务战略、资本市场活动及整体财务运营。自2024年起担任首席财务官的Anne Johnson，将在Faerm先生任命生效后转任首席会计官。Atai Beckley首席执行官兼联合创始人Srinivas Rao表示：\"我们非常高兴欢迎Mike Faerm加入Atai Beckley担任首席财务官。除非适用法律要求，Atai Beckley不承担更新或修订本新闻稿中任何前瞻性陈述的义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4232","BK4022","R","BK4539","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609829588","title":"Ataibeckley Inc.盘中异动 早盘股价大跌5.26%报3.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609829588","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609829588?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:42","pubTimestamp":1770302565,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日22时42分，Ataibeckley Inc.股票出现波动，股价大幅下挫5.26%。截至发稿，该股报3.42美元/股，成交量85.3022万股，换手率0.23%，振幅5.81%。Ataibeckley Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Ataibeckley Inc.公司简介：AtaiBeckley Inc是一家处于临床试验阶段的生物制药企业，其使命是通过研发有效、见效迅速且便捷的心理健康治疗方案来改善患者状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205224246a6d7a8d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205224246a6d7a8d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["R","BK4022","BK4232","BK4007","BK4539","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605281901","title":"Ataibeckley Inc.盘中异动 临近收盘急速拉升5.04%报4.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605281901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605281901?lang=zh_cn&edition=full","pubTime":"2026-01-24 04:55","pubTimestamp":1769201723,"startTime":"0","endTime":"0","summary":"北京时间2026年01月24日04时55分，Ataibeckley Inc.股票出现波动，股价大幅上涨5.04%。截至发稿，该股报4.17美元/股，成交量443.616万股，换手率1.22%，振幅6.68%。Ataibeckley Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Ataibeckley Inc.公司简介：AtaiBeckley Inc是一家处于临床试验阶段的生物制药企业，其使命是通过研发有效、见效迅速且便捷的心理健康治疗方案来改善患者状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124045523a44f889a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260124045523a44f889a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4022","ATAI","BK4232","BK4007","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512162306","title":"Atai Life Sciences N.V.盘中异动 早盘快速跳水5.22%报2.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512162306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512162306?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:19","pubTimestamp":1739895561,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时19分，Atai Life Sciences N.V.股票出现波动，股价急速跳水5.22%。截至发稿，该股报2.18美元/股，成交量179.687万股，换手率0.93%，振幅8.70%。Atai Life Sciences N.V.股票所在的生物技术行业中，整体涨幅为0.78%。Atai Life Sciences N.V.公司简介：ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219001921988a104d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219001921988a104d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511699714","title":"Atai Life Sciences N.V.盘中异动 早盘快速上涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699714","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511699714?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:49","pubTimestamp":1739544587,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时49分，Atai Life Sciences N.V.股票出现波动，股价快速上涨5.29%。Atai Life Sciences N.V.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1895.86%、494.63%、424.75%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为66.93%、32.93%、32.49%。Atai Life Sciences N.V.公司简介：ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224947abcf0ac8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224947abcf0ac8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRPX","ATAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511052513","title":"Atai Life Sciences N.V.盘中异动 早盘股价大跌9.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511052513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511052513?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:31","pubTimestamp":1739457114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时31分，Atai Life Sciences N.V.股票出现异动，股价急速下挫9.02%。Atai Life Sciences N.V.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为978.83%、802.55%、104.16%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Plus Therapeutics, Inc.，振幅分别为30.00%、25.80%、12.50%。Atai Life Sciences N.V.公司简介：ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223154abcdb235&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223154abcdb235&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATAI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510338936","title":"Atai Life Sciences N.V.盘中异动 早盘股价大涨5.32%报2.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338936?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:46","pubTimestamp":1739285198,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时46分，Atai Life Sciences N.V.股票出现异动，股价急速拉升5.32%。截至发稿，该股报2.34美元/股，成交量39.1617万股，换手率0.23%，振幅8.09%。Atai Life Sciences N.V.股票所在的生物技术行业中，整体跌幅为1.60%。Atai Life Sciences N.V.公司简介：ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112246389881bff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112246389881bff2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","BK4007","OCEA","ATAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510631588","title":"Atai Life Sciences N.V.盘中异动 早盘股价大涨6.79%报2.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510631588","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510631588?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:32","pubTimestamp":1739197964,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时32分，Atai Life Sciences N.V.股票出现波动，股价急速拉升6.79%。截至发稿，该股报2.33美元/股，成交量20.3016万股，换手率0.12%，振幅3.51%。Atai Life Sciences N.V.股票所在的生物技术行业中，整体涨幅为0.33%。Atai Life Sciences N.V.公司简介：ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223244abc9a55e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223244abc9a55e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","OCEA","ATAI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ataibeckley.com;ir.ataibeckley.com","stockEarnings":[{"period":"1week","weight":0.0168},{"period":"1month","weight":0.1187},{"period":"3month","weight":0.1844},{"period":"6month","weight":0.06},{"period":"1year","weight":2.0071},{"period":"ytd","weight":0.0367}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AtaiBeckley Inc.于2020年9月10日根据荷兰法律注册。2021年1月11日，更名为ATAI Life Sciences B.V.。2025年11月5日，更名为Atai Beckley N.V.。2026年1月2日，公司名称变更为AtaiBeckley Inc.，并转变为根据特拉华州法律注册成立的公司。该公司是一家临床阶段的生物技术公司，专注于为难以治疗的心理健康疾病开发新型的、基于迷幻药的神经可塑性药物。其研发管线包括针对难治性抑郁症和社交焦虑障碍的研究项目，以及一个针对新型非致幻化合物的药物发现项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.057026},{"month":2,"riseRate":0.6,"avgChangeRate":0.037147},{"month":3,"riseRate":0.4,"avgChangeRate":-0.050898},{"month":4,"riseRate":0.8,"avgChangeRate":0.036247},{"month":5,"riseRate":0.4,"avgChangeRate":0.043414},{"month":6,"riseRate":0,"avgChangeRate":-0.082337},{"month":7,"riseRate":0.8,"avgChangeRate":0.230191},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017917},{"month":9,"riseRate":0.2,"avgChangeRate":-0.094209},{"month":10,"riseRate":0.2,"avgChangeRate":-0.030207},{"month":11,"riseRate":0.4,"avgChangeRate":0.02801},{"month":12,"riseRate":0.4,"avgChangeRate":-0.079437}],"exchange":"NASDAQ","name":"Atai Beckley Inc","nameEN":"Atai Beckley Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atai Beckley Inc(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atai Beckley Inc(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atai Beckley Inc,ATAI,Atai Beckley Inc股票,Atai Beckley Inc股票老虎,Atai Beckley Inc股票老虎国际,Atai Beckley Inc行情,Atai Beckley Inc股票行情,Atai Beckley Inc股价,Atai Beckley Inc股市,Atai Beckley Inc股票价格,Atai Beckley Inc股票交易,Atai Beckley Inc股票购买,Atai Beckley Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atai Beckley Inc(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atai Beckley Inc(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}